In Silico臨床試驗市場 - 全球產業規模、佔有率、趨勢、競爭格局、機會及預測（按產業、治療領域、地區和競爭格局分類，2021-2031年）

全球In Silico臨床試驗市場預計將從 2025 年的 45.8 億美元成長到 2031 年的 72.2 億美元，複合年成長率為 7.88%。

此領域利用電腦建模和模擬技術，在虛擬病患群中評估藥物和醫療設備的療效和安全性，評估過程可與人體試驗同步進行，也可先於人體試驗。推動該市場發展的關鍵因素包括傳統研發成本的不斷攀升、減少動物試驗的倫理要求，以及縮短新治療方法上市時間的需求。根據藥物資訊協會 (DIA) 2024 年引用的一項專家分析顯示，在某些研發階段，採用此類計算模擬技術可將效率提高高達 90%。

然而，阻礙市場成長的一大障礙是這些計算模型監管檢驗的複雜性。證明虛擬模擬模型的可靠性符合嚴格的監管要求仍然是一項複雜的挑戰，這主要是因為目前用於驗證這些模型預測準確性（以實際人類生物數據為依據）的行業框架仍處於起步階段。缺乏成熟的檢驗標準對商業性應用構成了重大障礙。

市場促進因素

傳統臨床試驗成本和複雜性的不斷增加是推動製藥業轉向In Silico方法的主要促進因素。隨著生物標的日益複雜，進行大規模的實體試驗的經濟負擔變得難以承受，因此需要建立虛擬隊列，以便在人體試驗前評估療效。生成式工作流程的最新趨勢凸顯了縮短研發週期的必要性，這些工作流程使企業能夠繞過冗長的傳統步驟。例如，在2024年3月的新聞稿中， In Silico Medicine公司報告稱，發表在《自然·生物技術》雜誌上的一項研究表明，其人工智慧平台在大約18個月內識別出了候選治療藥物。這顯著縮短了通常長達數年的臨床前研究週期，表明計算模型可以降低後期研發失敗的風險並改善資源管理。

此外，人工智慧和高效能運算的快速發展透過提高虛擬模擬的預測精度，推動了市場成長。從靜態模型到動態生成演算法的轉變，使得創建能夠模擬人體生理反應的高精度數位雙胞胎模型成為可能。 2024年5月，GoogleDeepMind發布了升級版的「AlphaFold 3」模型，該模型將蛋白質-分子相互作用預測的準確率提高了50%，提供了可靠虛擬測試所需的詳細數據。基於這項技術進步，Xaira Therapeutics於2024年4月成立，投資超過10億美元，並大力投資以擴展這些能力，並將這些先進的計算技術融入藥物研發的整個生命週期。

市場挑戰

計算模型獲得監管部門核准的複雜流程是全球In Silico臨床試驗市場成長的一大障礙。儘管模擬技術在理論上具有很高的效率，但要證明這些虛擬方法能夠滿足嚴格的安全標準仍然極具挑戰性。監管機構要求提供強力的證據，證明電腦模型可以準確預測人體生物反應，但目前業界缺乏一套完善的標準化框架來持續證明這種可靠性。因此，藥物研發者在核准過程中面臨巨大的不確定性和被拒風險，這阻礙了他們投入必要的資金從傳統方法過渡到虛擬患者群。

由於缺乏用於模型檢驗的高品質真實世界數據，這項挑戰更加嚴峻。與精確的人類生物資料集進行廣泛的基準測試對於確認預測準確性至關重要，但此類數據通常分散或難以獲得。根據皮斯托亞聯盟2024年的調查，52%的生命科學專業人士認為低品質且控制不佳的資料集是採用這些先進計算技術的主要障礙。缺乏可靠的檢驗數據直接加劇了監管方面的挑戰，阻礙了企業累積市場核准所需的有力證據，並延緩了In Silico測試的商業性化應用。

市場趨勢

為虛擬患者群體創建高精度數位雙胞胎，從根本上改變了監管申報流程，使開發人員無需招募患者即可模擬藥物在不同生理人群中的表現。這種轉變在廣泛應用基於生理的藥物動力學模型生成虛擬隊列方面尤其明顯，這些模型能夠預測特定族群（例如兒童患者或器官功能受損患者）的藥物交互作用。因此，製藥公司擴大直接使用這些模擬來獲得適應症核准，實際上取代了某些體內研究。正如 Certara 在 2024 年 9 月發布的「Simcyp 聯盟成立 25 週年」公告中所指出的，其平台生成的模擬已成功指導了 115 種藥物的 375 多項適應症決策，取代了實際的臨床試驗。

同時，虛擬對照組的使用正在重新定義試驗設計，使申辦者能夠以基於歷史臨床記錄產生的合成數據取代傳統的安慰劑組。這種方法在腫瘤學和罕見疾病研究領域已被廣泛應用，因為在這些領域，招募足夠數量的受試者來建立標準對照組往往在倫理上具有挑戰性，或在實踐中難以實現。透過利用龐大的歷史資料集，研究人員可以建立統計上有效的外部對照組，從而在保持科學嚴謹性的同時，顯著減少患者招募的需求。根據Medidata公司2024年8月發布的報告《符合監管要求的外部對照組》，該公司用於創建這些合成對照組的專有資料庫目前包含來自超過33,000項臨床試驗和1000多萬名患者的歷史臨床試驗數據，為這些混合試驗模型提供了必要的詳細證據。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球In Silico臨床試驗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按行業分類（醫療設備與藥品）
  • 依治療領域（腫瘤科、神經科、心臟科、感染疾病、整形外科、皮膚科、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美In Silico臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲In Silico臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區In Silico臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲In Silico臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲In Silico臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球In Silico臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Dassault Systemes
• Certara
• Insilico Medicine
• GNS Healthcare
• Siemens Healthineers
• Evidera
• Novadiscovery
• Simulations Plus
• Genentech
• Physiomics

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global In Silico Clinical Trials Market is projected to expand from USD 4.58 Billion in 2025 to USD 7.22 Billion by 2031, reflecting a compound annual growth rate of 7.88%. This sector employs computer modeling and simulation to assess the efficacy and safety of pharmaceuticals and medical devices within virtual patient groups, occurring either alongside or prior to human testing. Key factors propelling this market include the escalating expenses associated with traditional research and development, the ethical imperative to minimize animal testing, and the necessity to expedite new therapies' time to market. Expert analysis cited by the Drug Information Association in 2024 suggests that incorporating these computational simulations could boost efficiency by up to 90% during certain developmental phases.

However, a major obstacle hindering market growth is the intricate nature of regulatory validation for these computational models. Demonstrating the reliability of virtual simulations to meet strict regulatory requirements remains a complex task, primarily because industry frameworks for confirming the predictive accuracy of these models against actual human biological data are still evolving. This lack of mature verification standards creates a significant barrier to widespread commercial adoption.

Market Driver

The rising expense and intricacy of conventional clinical trials are the main factors driving the pharmaceutical sector toward in silico methods. As biological targets grow more complex, the financial strain of running extensive physical trials has become unmanageable, necessitating virtual cohorts that can evaluate efficacy prior to human involvement. This need to shorten development cycles is highlighted by recent advancements in generative workflows that enable companies to skip prolonged traditional steps. For instance, Insilico Medicine reported in a March 2024 press release regarding a study in 'Nature Biotechnology' that their AI-powered platform identified a therapeutic candidate in roughly 18 months, a timeframe notably shorter than the standard multi-year preclinical period, demonstrating how computational models can lower the risk of late-stage failures and improve resource management.

Furthermore, rapid developments in artificial intelligence and high-performance computing are fueling market growth by improving the predictive accuracy of virtual simulations. Moving from static models to dynamic, generative algorithms enables the creation of highly precise digital twins that mimic human physiological reactions. In May 2024, Google DeepMind announced that their upgraded 'AlphaFold 3' model secured a 50% increase in prediction accuracy for protein-molecule interactions, offering the detailed data needed for dependable virtual testing. This technological progress has prompted significant investment to scale these capabilities, as seen in April 2024 when Xaira Therapeutics launched with over USD 1 billion in committed capital to embed these advanced computational techniques into the entire drug development lifecycle.

Market Challenge

The intricate process of obtaining regulatory validation for computational models poses a significant barrier to the growth of the Global In Silico Clinical Trials Market. Although simulation technologies promise theoretical efficiency, proving the credibility of these virtual approaches to meet rigorous safety standards remains challenging. Regulatory authorities demand solid proof that computer models can precisely forecast human biological responses, yet the sector currently lacks fully developed, standardized frameworks to consistently prove this reliability. As a result, pharmaceutical developers encounter considerable uncertainty and the threat of rejection during approval procedures, which deters the financial commitment needed to shift from conventional techniques to virtual patient cohorts.

This challenge is further compounded by the struggle to access high-quality real-world data required to verify these models. Confirming predictive accuracy necessitates extensive benchmarking against exact human biological datasets, which are frequently fragmented or inaccessible. According to the Pistoia Alliance in 2024, 52% of life science professionals identified low-quality and poorly curated datasets as the primary obstacle to implementing these sophisticated computational technologies. This lack of reliable validation data directly worsens regulatory difficulties, hindering companies from compiling the strong evidence dossiers required for market approval and delaying the commercial uptake of in silico trials.

Market Trends

The creation of high-fidelity digital twins for virtual patient cohorts is fundamentally transforming regulatory submissions by enabling developers to model drug performance across varied physiological populations without the need for human recruitment. This shift is especially apparent in the broad use of physiologically based pharmacokinetic modeling, which creates virtual cohorts to forecast drug interactions in specific demographics, such as pediatric patients or individuals with organ impairment. Consequently, pharmaceutical firms are increasingly utilizing these simulations to obtain label approvals directly, effectively substituting for certain in vivo studies. As noted by Certara in their September 2024 'Simcyp Consortium Celebrates 25th Anniversary' announcement, their platform's simulations have successfully guided dosing decisions for over 375 label claims covering 115 different drugs, replacing physical clinical trials.

Concurrently, the use of virtual control arms is redefining trial design by allowing sponsors to replace conventional placebo groups with synthetic data generated from historical clinical records. This method is gaining considerable momentum in oncology and rare disease research, where enrolling enough participants for standard control arms is often ethically difficult or logistically impractical. By leveraging extensive historical datasets, researchers can build statistically sound external comparators that uphold scientific rigor while significantly lowering patient enrollment needs. According to Medidata's August 2024 report on 'The Regulatory Grade External Control Arm', their proprietary database for creating these synthetic arms now includes historical clinical trial data from more than 33,000 trials and 10 million patients, offering the detailed evidence needed to sustain these hybrid trial models.

Key Market Players

• Dassault Systemes
• Certara
• Insilico Medicine
• GNS Healthcare
• Siemens Healthineers
• Evidera
• Novadiscovery
• Simulations Plus
• Genentech
• Physiomics

Report Scope

In this report, the Global In Silico Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Silico Clinical Trials Market, By Industry

• Medical Devices v/s Pharmaceuticals

In Silico Clinical Trials Market, By Therapeutic Area

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Orthopedic
• Dermatology
• Others

In Silico Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Silico Clinical Trials Market.

Available Customizations:

Global In Silico Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In Silico Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Industry (Medical Devices v/s Pharmaceuticals)
  • 5.2.2. By Therapeutic Area (Oncology, Neurology, Cardiology, Infectious Diseases, Orthopedic, Dermatology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America In Silico Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Industry
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In Silico Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Industry
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada In Silico Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Industry
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico In Silico Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Industry
      • 6.3.3.2.2. By Therapeutic Area

7. Europe In Silico Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Industry
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany In Silico Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Industry
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France In Silico Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Industry
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom In Silico Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Industry
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy In Silico Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Industry
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain In Silico Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Industry
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific In Silico Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Industry
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China In Silico Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Industry
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India In Silico Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Industry
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan In Silico Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Industry
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea In Silico Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Industry
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia In Silico Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Industry
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa In Silico Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Industry
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia In Silico Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Industry
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE In Silico Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Industry
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa In Silico Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Industry
      • 9.3.3.2.2. By Therapeutic Area

10. South America In Silico Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Industry
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil In Silico Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Industry
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia In Silico Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Industry
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina In Silico Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Industry
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global In Silico Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Dassault Systemes
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Certara
• 15.3. Insilico Medicine
• 15.4. GNS Healthcare
• 15.5. Siemens Healthineers
• 15.6. Evidera
• 15.7. Novadiscovery
• 15.8. Simulations Plus
• 15.9. Genentech
• 15.10. Physiomics

16. Strategic Recommendations

17. About Us & Disclaimer